Is GlaxoSmithKline a high-yield dividend star or a dangerous dog of the FTSE 100?

How sustainable is the GlaxoSmithKline plc (LON: GSK) dividend?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You can get decent investing results by collecting dividends from high-yielding stocks and reinvesting them to compound your gains. However, that strategy only works well as long as the stocks you buy and hold have sustainable dividends.

Is the 5%-plus dividend yield for pharmaceutical giant GlaxoSmithKline (LSE: GSK) sustainable? This table summarises the recent financial record:

Year

2013

2014

2015

2016

2017

Net cash from operations (£m)

7,222

5,176

2,569

6,497

6,918

Profit before tax (£m)

6,647

2,968

10,526

1,939

3,525

Adjusted earnings per share

108.4p

95.4p

75.7p

102.4p

111.8p

Dividend per share

78p

80p

80p

80p

80p

Cash flow generally supports profits well. But neither cash flow, earnings or the dividend have moved up over the past four years, suggesting that GlaxoSmithKline is struggling to grow.

Grinding on

Back in April with the first quarter results report, chief executive Emma Walmsley told us that the company made good progress in the first part of the year, with sales growth across all operational businesses. Recent product launches included Shingrix, Trelegy and Juluca, which, along with other new releases, are contributing to improvements in the firm’s adjusted operating margin. 

However, the problem of patent expiry still dogs the firm and sometimes it seems as if two steps back follow every two steps forward, as the recent stagnant dividend attests. The firm saw “increased pricing and competitive pressures” in the US inhaled respiratory market during the first quarter and expects a decline of around 30% in sales of Advair in the US during 2018. Overall, the directors think earnings per share will grow 4-7% this year, suggesting some progress, although probably not enough to get the dividend moving up again.

The company has agreed with Novartis to acquire its Consumer Healthcare business for $13bn, subject to shareholder approval. The directors said the acquisition will “improve future cash generation and support capital planning” with the aim of strengthening the pharmaceuticals business and the research and development (R&D) pipeline. I reckon boosting that R&D pipeline is the firm’s best hope for getting the dividend to expand in the future, so the Novartis move could mark a turning point for GlaxoSmithKline.

GlaxoSmithKline’s dividend sustainability score

Let’s look at three different features to judge whether the company’s dividend seems sustainable with each indicator scored out of a possible five points:

  1. Dividend cover: adjusted earnings covered last year’s dividend almost 1.4 times. 2/5
  2. Cash flow: generally, cash flow covers profits well but has not grown in four years. 4/5
  3. Outlook and trading: recent trading has been good and the outlook is satisfactory. 4/5

Overall, I score GlaxoSmithKline 10 out of 15, which makes me a little cautious about the sustainability of the firm’s dividend, particularly with the ongoing drag from generic competition. The static dividend demonstrates how tough things have been for the firm and I’m not expecting the dividend to rise much over the next year or two. That said, I think GlaxoSmithKline could be a decent stock to hold for very patient investors because of the defensive characteristics of the sector.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

With a spare £500 I’d buy these UK shares

A financial services giant, a FTSE 250 distributor, a FTSE 100 tech stock, and a gold miner are on the…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Should I buy this defensive FTSE 100 stock for growth and returns?

This Fool takes a closer look at a FTSE 100 stock to see if it could boost his holdings via…

Read more »

Young female analyst working at her desk in the office
Investing Articles

I robbed Mr Market of this cheap FTSE stock!

This FTSE 250 stock has crashed by almost 30% in six months. But I recently bought into this battered business…

Read more »

Mature people enjoying time together during road trip
Investing Articles

3 reasons I’m backing NIO shares to soar!

NIO shares have bounced up and down this year. But where will the share price go next? My bet is…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Up 300%, is the Hurricane Energy share price an opportunity too good to miss?

This Fool looks at why the Hurricane Energy share price has soared in the past 12 months. Should he buy…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

The BT share price crashes 20% in a month. Buy now?

The BT share price has crashed by almost a fifth since coming close to £2 on 12 July. After this…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

How I’d invest £1,000 in growth shares today to target £5,000 in a decade

Our writer reckons he could do well by choosing the right growth shares today and holding them in his portfolio…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

How passive income from stocks can speed up early retirement

By investing patiently over the years, buying quality shares has given me enough passive income to retire 10 or even…

Read more »